Back
Compare AU
Compare IAF vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares Core Composite Bond ETF (IAF) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IAF | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 515 | 72 |
Median incremental investment | $1,069.51 | $683.16 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,038.40 | $2,356.52 |
Average age group | > 35 | > 35 |
Key Summary
IAF | CURE | |
|---|---|---|
Strategy | IAF.AX was created on 2012-03-12 by iShares. The fund's investment portfolio concentrates primarily on investment grade fixed income. The ETF currently has 3247.06m in AUM and 594 holdings. The fund aims to provide investors with the performance of the Bloomberg AusBond Composite 0+ Yr IndexSM, before fees and expenses. The index is designed to measure the performance of the Australian bond market and includes investment grade fixed income securities issued by the Australian Treasury. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 47.2m in AUM and 148 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | AUSTRALIA (COMMONWEALTH OF) RegS (2.49 %) AUSTRALIA (COMMONWEALTH OF) RegS (2.44 %) AUSTRALIA (COMMONWEALTH OF) RegS (2.40 %) | Apogee Therapeutics Inc (1.57 %) Twist Bioscience Corp (1.56 %) Praxis Precision Medicines Inc Ordinary Shares (1.49 %) |
Top 3 industries | Other (99.31 %) Financials (0.25 %) Communication Services (0.19 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) | |
Management fee | 0.15 % | 0.45 % |
Key Summary
IAF | CURE | |
|---|---|---|
Issuer | iShares | Global X |
Tracking index | Bloomberg AusBond Composite 0+ Yr Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.15 % | 0.45 % |
Price | $101.28 | $74.81 |
Size | $3.731 billion | $47.195 million |
10Y return | -6.80 % | N/A |
Annual distribution yield (5Y) | 2.22 % | 0.03 % |
Market | ASX | ASX |
First listed date | 14/03/2012 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IAF | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 515 | 72 |
Median incremental investment | $1,069.51 | $683.16 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,038.40 | $2,356.52 |
Average age group | > 35 | > 35 |
Pros and Cons
IAF | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
IAF | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |